CO-DIAGNOSTICS INC (CODX)
US1897631057 - Common Stock
Overall CODX gets a fundamental rating of 3 out of 10. We evaluated CODX against 195 industry peers in the Health Care Equipment & Supplies industry. CODX has a great financial health rating, but its profitability evaluates not so good. CODX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year CODX has reported negative net income.
In the past year CODX has reported a negative cash flow from operations.
In multiple years CODX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CODX reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of CODX (-37.07%) is comparable to the rest of the industry.
CODX has a Return On Equity of -41.08%. This is comparable to the rest of the industry: CODX outperforms 51.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.07% | ||
| ROE | -41.08% | ||
| ROIC | N/A |
ROA(3y)-8.57%
ROA(5y)-49.58%
ROE(3y)-8.75%
ROE(5y)-65.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CODX's Gross Margin of 38.55% is on the low side compared to the rest of the industry. CODX is outperformed by 66.15% of its industry peers.
CODX's Gross Margin has declined in the last couple of years.
CODX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.84%
GM growth 5Y-12.46%
2. Health
2.1 Basic Checks
CODX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CODX has more shares outstanding than it did 1 year ago.
CODX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CODX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CODX has an Altman-Z score of 1.67. This is a bad value and indicates that CODX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CODX (1.67) is comparable to the rest of the industry.
There is no outstanding debt for CODX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.67 |
ROIC/WACCN/A
WACC10.08%
2.3 Liquidity
CODX has a Current Ratio of 10.81. This indicates that CODX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.81, CODX belongs to the best of the industry, outperforming 93.33% of the companies in the same industry.
CODX has a Quick Ratio of 10.52. This indicates that CODX is financially healthy and has no problem in meeting its short term obligations.
CODX has a better Quick ratio (10.52) than 93.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.81 | ||
| Quick Ratio | 10.52 |
3. Growth
3.1 Past
CODX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -163.04%.
Looking at the last year, CODX shows a very negative growth in Revenue. The Revenue has decreased by -80.08% in the last year.
CODX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 179.41% yearly.
EPS 1Y (TTM)-163.04%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q26.47%
Revenue 1Y (TTM)-80.08%
Revenue growth 3Y-54.96%
Revenue growth 5Y179.41%
Revenue growth Q2Q153.94%
3.2 Future
The Earnings Per Share is expected to grow by 38.41% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.55%
EPS Next 2Y38.41%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-15.36%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CODX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CODX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CODX's earnings are expected to grow with 38.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.41%
EPS Next 3YN/A
5. Dividend
5.1 Amount
CODX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CO-DIAGNOSTICS INC
NASDAQ:CODX (4/26/2024, 7:00:00 PM)
1.11
-0.03 (-2.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap34.70M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.07% | ||
| ROE | -41.08% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.55% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.81 | ||
| Quick Ratio | 10.52 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-163.04%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y16.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-80.08%
Revenue growth 3Y-54.96%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y